The synergistic effect of BMA s+ ICIs has been reported by preclinical studies in other solid tumors (PC, NSCLC, and melanoma) with BoM [11,12,48], which demonstrated survival benefits and delay of primary tumor progression. The gene discussed is GRHL2; the disease is melanoma.